{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:10:14Z","timestamp":1772835014278,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-114916"],"award-info":[{"award-number":["MOP-114916"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.neuropharm.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T04:45:13Z","timestamp":1438836313000},"page":"356-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications"],"prefix":"10.1016","volume":"99","author":[{"given":"Nicolas","family":"Morin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H.","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.08.002_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0304-3940(92)90198-G","article-title":"Activation of D1 receptors stimulates accumulation of gamma-aminobutyric acid in slices of the pars reticulata of 6-hydroxydopamine-lesioned rats","volume":"145","author":"Aceves","year":"1992","journal-title":"Neurosci. Lett."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2015.08.002_bib2","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/mds.870040514","article-title":"Biochemistry of Parkinson's disease 28 years later: a critical review","volume":"4","author":"Agid","year":"1989","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0304-3940(00)00788-6","article-title":"Cloning of serotonin 5-HT(1) receptor subtypes from the chimpanzee, gorilla and Rhesus monkey and their agonist-induced guanosine 5'gamma(35)S triphosphate binding","volume":"280","author":"Alberts","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neures.2013.10.002","article-title":"Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia","volume":"77","author":"Bezard","year":"2013","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib5","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0306-4522(94)90164-3","article-title":"The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals","volume":"58","author":"Boschert","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1113\/jphysiol.2003.053843","article-title":"The modulation by 5-HT of glutamatergic inputs from the raphe pallidus to rat hypoglossal motoneurons, in\u00a0vitro","volume":"553","author":"Bouryi","year":"2003","journal-title":"J.\u00a0Physiol."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2015.08.002_bib8","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia","volume":"23","author":"Calabresi","year":"2008","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias","volume":"61","author":"Calon","year":"2002","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/mds.10343","article-title":"Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications","volume":"18","author":"Calon","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0006-8993(97)01566-7","article-title":"5-HT1B receptor binding in degenerative movement disorders","volume":"790","author":"Castro","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib15","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2015.08.002_bib16","first-page":"II36","article-title":"Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms","volume":"247","author":"Chase","year":"2000","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1476-5381.1995.tb13321.x","article-title":"Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors","volume":"114","author":"Davidson","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: on movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V","article-title":"Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys","volume":"39","author":"Frechilla","year":"2001","journal-title":"Synapse"},{"issue":"Pt 6","key":"10.1016\/j.neuropharm.2015.08.002_bib21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1242\/jcs.112.6.967","article-title":"Differential addressing of 5-HT1A and 5-HT1B receptors in epithelial cells and neurons","volume":"112","author":"Ghavami","year":"1999","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1098-2396(19990601)32:3<153::AID-SYN2>3.0.CO;2-X","article-title":"Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys","volume":"32","author":"Goulet","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.294.5544.1024","article-title":"The neurobiology of slow synaptic transmission","volume":"294","author":"Greengard","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","article-title":"Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys","volume":"186","author":"Gr\u00e9goire","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib25","first-page":"13","article-title":"Brain Monoamines and Parkinsonism","author":"Hornykiewicz","year":"1975"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib28","doi-asserted-by":"crossref","first-page":"194.e5","DOI":"10.1016\/j.neurobiolaging.2010.04.035","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2013.09.003","article-title":"Modulating mGluR5 and 5-HT1A\/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action","volume":"250","author":"Iderberg","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib30","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/WNR.0b013e3283300fd7","article-title":"Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia","volume":"20","author":"Jaunarajs","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib32","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1016\/S0021-9258(18)42612-9","article-title":"Characterization of the human 5-hydroxytryptamine1B receptor","volume":"267","author":"Jin","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ana.410200106","article-title":"Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss","volume":"20","author":"Kish","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib34","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib35","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1111\/j.1460-9568.2006.05222.x","article-title":"Selective 5-HT receptor inhibition of glutamatergic and GABAergic synaptic activity in the rat dorsal and median raphe","volume":"24","author":"Lemos","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","article-title":"Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA","volume":"1046","author":"Maeda","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib37","series-title":"Atlas of the Human Brain","author":"Mai","year":"1997"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib38","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1468-2982.2002.00459.x","article-title":"Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633","volume":"22","author":"McCall","year":"2002","journal-title":"Ceph. Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/mol.58.6.1271","article-title":"Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors","volume":"58","author":"Morikawa","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.20654","article-title":"Prevention of levodopa-induced dyskinesias by a selective NR1A\/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin","volume":"21","author":"Morissette","year":"2006","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib45","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain a J. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib46","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1046\/j.1460-9568.1998.00248.x","article-title":"Serotonin inhibits synaptic glutamate currents in rat nucleus accumbens neurons via presynaptic 5-HT1B receptors","volume":"10","author":"Muramatsu","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/323686","article-title":"Imbalanced dopaminergic transmission mediated by serotonergic neurons in L-DOPA-induced dyskinesia","volume":"2012","author":"Navailles","year":"2012","journal-title":"Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/syn.20006","article-title":"L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease","volume":"52","author":"Ochi","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/360161a0","article-title":"A\u00a0single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors","volume":"360","author":"Oksenberg","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12031-008-9137-8","article-title":"Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias","volume":"38","author":"Ouattara","year":"2009","journal-title":"J.\u00a0Mol. Neurosci. MN"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-4159.2010.06635.x","article-title":"Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys","volume":"113","author":"Ouattara","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib52","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib53","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.10031","article-title":"Clinical-pathological study of levodopa complications","volume":"17","author":"Rajput","year":"2002","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib55","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1152\/jn.1994.72.5.2438","article-title":"Effects of 5-HT on thalamocortical synaptic transmission in the developing rat","volume":"72","author":"Rhoades","year":"1994","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib56","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuint.2012.08.009","article-title":"Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain","volume":"61","author":"Riahi","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib57","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","article-title":"Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias","volume":"33","author":"Riahi","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib58","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bcp.2013.08.005","article-title":"Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia","volume":"86","author":"Riahi","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib59","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib60","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/NEN.0b013e31819cabe4","article-title":"Metabotropic glutamate receptor II in the brains of Parkinsonian patients","volume":"68","author":"Samadi","year":"2009","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib61","first-page":"19","article-title":"Functional neurochemistry of the basal ganglia","volume":"vol. 83","author":"Samadi","year":"2007"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/PL00005321","article-title":"5-HT1B receptors modulate release of [3H]dopamine from rat striatal synaptosomes","volume":"359","author":"Sarhan","year":"1999","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s002109900163","article-title":"5-HT1B receptors modulate release of [3H]dopamine from rat striatal synaptosomes: further evidence using 5-HT moduline, polyclonal 5-HT1B receptor antibodies and 5-HT1B receptor knock-out mice","volume":"361","author":"Sarhan","year":"2000","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib64","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib65","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","article-title":"Novel pharmacological targets for the treatment of Parkinson's disease","volume":"5","author":"Schapira","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.034439","article-title":"Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities","volume":"303","author":"Schwarcz","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib67","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1523\/JNEUROSCI.16-23-07566.1996","article-title":"Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in\u00a0vitro","volume":"16","author":"Stanford","year":"1996","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib68","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cne.902220208","article-title":"A\u00a0stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)","volume":"222","author":"Szabo","year":"1984","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib69","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1152\/jn.1993.69.5.1749","article-title":"Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex","volume":"69","author":"Tanaka","year":"1993","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hbm.20035","article-title":"Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain","volume":"22","author":"Varnas","year":"2004","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.neurobiolaging.2013.08.025","article-title":"Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease","volume":"35","author":"Varrone","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib72","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib73","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainres.2006.09.027","article-title":"Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata","volume":"1123","author":"Yamamoto","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.08.002_bib74","first-page":"2163","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism","volume":"vol. 105","author":"Zhang","year":"2008"},{"key":"10.1016\/j.neuropharm.2015.08.002_bib75","first-page":"2163","article-title":"Study on effect of drought stress on physiological adaptation of seedlings of Atractylodes lancea","volume":"33","author":"Zhou","year":"2008","journal-title":"Zhongguo Zhong yao za zhi\u00a0= Zhongguo zhongyao zazhi\u00a0= China J. Chin. Mater. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815300484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815300484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:09:59Z","timestamp":1748556599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815300484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":75,"alternative-id":["S0028390815300484"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.08.002","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}